Fibrinogen and fibrin: Biochemistry and pathophysiology

Critical Reviews in Oncology and Hematology

Volumn 6, Issue 2, 1986, Pages 97-146

  Budzynski, Andrei Z ^a   Shainoff, John R ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; DISULFIDE; FIBRIN; FIBRINOGEN; MONOCLONAL ANTIBODY; PEPTIDE HYDROLASE; PLASMA PROTEIN; PLASMIN; POLYMER; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

AMINO ACID SEQUENCE; ANIMAL; BLOOD CLOTTING; CHEMISTRY; FIBRINOLYSIS; HUMAN; MACROMOLECULE; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; REVIEW;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION; BLOOD PROTEINS; CARBOHYDRATES; CHEMISTRY; DISULFIDES; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HUMAN; MACROMOLECULAR SYSTEMS; PEPTIDE HYDROLASES; PLASMIN; POLYMERS; PROTEIN CONFORMATION; SUPPORT, U.S. GOV'T, P.H.S.; TRANSGLUTAMINASES;

EID: 0022961165     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(86)80019-1     Document Type: Article

References (372)

1. Fibrinogen structure and physiology
2. Fibrin: structure and interactions
3. Fibrinogen and Fibrin
4. Fibrinogen—recent biochemical and medical aspects
5. Fibrinogen—recent biochemical and medical aspects
6. THE CONVERSION OF FIBRINOGEN TO FIBRIN: EVENTS AND RECOLLECTIONS FROM 1942 TO 1982
7. The Size and Shape of Bovine Fibrinogen. Studies of Sedimentation, Diffusion and Viscosity1
8. Equilibria in the Fibrinogen-Fibrin Conversion. III. Heats of Polymerization and Clotting of Fibrin Monomer1
9. The fibrinogen molecule: its size, shape and mode of polymrization
10. Electron Microscopic Investigation of the Shape of Fibrinogen Nodules: a Model for Certain Proteins
11. Size and shape of fibrinogen, 1. Electron microscopy of the hydrated molecule
12. A neutron small-angle scattering study of bovine fibrinogen
13. Fibrinogen: agreement of experimental and calculated hydrodynamic data with electron-microscopic models
14. Some physicochemical properties of human fibrinogen
15. Physicochemical studies on bovine fibrinogen. I. Molecular weight and hydrodynamic properties of fibrinogen and fibrinogen cleaved by sulfite in 5 M guanidine-HCl solution
16. Preparation and properties of serum and plasma proteins. XII. The refractive properties of human plasma and certain purified fractions
17. Partial specific volume for some porcine and bovine plasma protein fractions
18. Molecular weight of bovine fibrinogen by sedimentation equilibrium
19. Molecular structure of fibrinogen. I. Helical content and the role of the tyrosine moiety in the fibrinogen molecule
20. Physiochemical studies of bovine fibrinogen. III. Optical rotation of the native and denatured molecules
21. Difference in conformation of fibrinogen degradation products as revealed by hydrogen exchange and spectropolarimetry
22. Conformation of fibrinogen. Calorimetric evidence for a threenodule structure
23. Domains in the fibrinogen molecule
24. The proteins of skeletal muscle
25. The amino acid sequence of the α-chain of human fibrinogen
26. Amino acid sequences of human fibrin. Preliminary note on the completion of the intermediate part of the α-chain sequence
27. Characterization of a complementary deoxyribonucleic acid coding for the α chain of human fibrinogen
28. Characterization of a complementary deoxyribonucleic acid and genomic deoxyribonucleic acid for the β chain of human fibrinogen
29. Characterization of a complementary deoxyribonucleic acid coding for the γ chain of human fibrinogen
30. Sequence homology between β-chain and γ-chain in human firbrin
31. Amino acid sequence of the β-chain of human fibrinogen: homology with the γ-chain
32. Expression of a cloned human fibrinogen cDNA in Escherichia coli: synthesis of an Aα polypeptide
33. Demonstration of a large molecular weight variant of the γ chain of normal human plasma
34. Human plasma fibrinogen heterogeneity: evidence for an extended carboxy-terminal sequence in a normal γ chain variant (γ′)
35. γ and γ′ chains of human fibrinogen are produced by alternative mRNA processing
36. Structure of the human γ-fibrinogen gene. Alternate mRNA splicing near the 3′ end of the gene produces γA and γB forms of the γ-fibrinogen
37. Structural and chromatographic heterogeneity of normal plasma fibirnogen associated with the presence of three γ chain types with distinct molecular weights
38. 2-terminal fragments of the alpha (A) chain
39. Dimeric half-molecules of human fibrinogen are joined through disulfide bonds in an anti-parallel orientation
40. Enzymatic reduction of disulfide bonds in fibrinogen by the thioredoxin system. I. Identification of reduced bonds and studies on reoxidation process
41. A method for characterizing serum fibrinogen and fibrin degradation products
42. Number and reactivity of disulfide bonds in fibrinogen and fibrinogen and fibrin
43. Human fibrinogen: sequence, sulfur bridges, glycosylation and some structural variants
44. Designation of sequences involved in the “coiled-coil” interdomainal connections in fibrinogen. Construction of an atomic scale model
45. Partial reduction of bovine fibrinogen by some sulphydryl compounds
46. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease
47. Dysfibrinogenemia associated with liver disease
48. Dysfibrinogenemia associated with hepatoma
49. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains
50. Human fetal fibrinogen: its characteristics of delayed fibrin formation, high sialic acid and AP peptide content are more marked in preterm than in term samples
51. Separation of both the Bβ- and the γ-polypeptide chains of human fibrinogen into two main types which differ in sialic acid content
52. A subfraction of human fibrinogen with high sialic acid content and elongated γ chains
53. Sialic acids and their role as biologic masks
54. Amino acid sequence of the N-terminal part of the α-chain in human fibrinogen
55. Partial chemical characterization of the isolated γ-chain of human fibrinogen
56. The release of carbohydrate moieties from human fibrinogen by almond glycopeptidase without alteration in fibrinogen clottability
57. Carbohydrate structure of human fibrinogen
58. Comparative studies on the structures of carbohydrate moieties of human fibrinogen and abnormal fibrinogen Nagoya
59. Glycosylated Aα chains in chicken fibrinogen
60. Glycosylation of human fibrinogen in vivo
61. Non-enzymatic glycosylation of fibrinogen
62. Electron microscopy of plasmic fragments of human fibrinogen as related to trinodular structure of the intact molecule
63. Morphology of bovine fibrinogen monomers and fibrin oligomers
64. Trinodular structure of fibrinogen. Confirmation by both shadowing and negative-stain electron microscopy
65. Location of peptide fragments in the fibrinogen molecule by immunoelectron microscopy
66. Shadow-cast electron microscopy of fibrinogen with antibody fragments bound to specific regions
67. Immune labeling of the D and E regions of human fibrinogen by electron microscopy
68. Band patterns seen by electron microscopy in ordered arrays of bovine and human fibrinogen and fibrin after negative staining
69. Crystalline states of a modified fibrinogen
70. Segments from modified human fibrinogen
71. Laser diffraction of oriented fibrinogen molecules
72. A model from electron microscopy for the molecular structure of fibrinogen and fibrin
73. The structure of fibrinogen and fibrin. I. Electron microscopy and X-ray crystallography of fibrinogen
74. Größe und gestalt des fibrinogenmoleküls, 3. Hydrodynamische studien
75. Größe und gestalt des fibrinogenmoleküls, 2. Röntgenkleinwinkelstreuung an verdünnten lösungen
76. Steady-state fluorescence polarization of dansylcadaverine-fibrinogen: evidence for flexibility
77. Structure organization of C-terminal parts by fibrinogen Aα-chains
78. Conformation of the carboxy-terminal region of the Aα chain of fibrinogen elucidated by immunochemical analysis
79. Structural aspects of the fibrinogen to fibrin coversion
80. Blood coagulation and fibrinolysis
81. Three-dimensional structure of an intract human immunoglobulin
82. Acceleration of fibrin polymerization by calcium ions
83. Denaturation of fibrinogen, the protective effect of calcium
84. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D
85. The binding of calcium to bovine fibrinogen
86. Ca binding of rat fibrinogen and fibrin(ogen) degradation products
87. Potential role of the Aα chain in the binding of calcium to human fibrinogen
88. Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen (plasmin fragments Y)
89. Evidence for the localization of a calcium-binding site in the amino-terminal disulphide knot of fibrin(ogen)
90. Fibrin polymerization sites in fibrinogen and fibrin fragments
91. 2+-related regulatory function of fibrinogen
92. Assay of bovine fibrinopeptides by high-performance liquid chromatography
93. Purification of human fibrinopeptides by high-performance liquid chromatography
94. Analysis of human fibrinopeptides by high-performance liquid chromatography
95. Evaluation of a commercial kit for the radioimmunoassay of fibrinopeptide A
96. On the N-terminal amino acids in fibrinogen and fibrin
97. The clotting of fibrinogen. II. Fractionation of peptide material liberated
98. Kinetics of fibrin oligomer formation observed by electron microscopy
99. Steady-state kinetic study of the bovine thrombin-fibrinogen interaction
100. Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides
101. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin
102. Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin
103. Fibrinopeptide release from fibrinogen
104. On the Significance of the Release of Two Different Peptides from Fibrinogen During Clotting.
105. Fibrin assembly: a comparison of electron microscopic and light scattering results
106. A two-step fibrinogen–fibrin transition in blood coagulation
107. The effects of fibrinopeptide cleavage on the plasmic degradation pathways of human cross-linked fibrin
108. Fibrinopeptide B and aggregation of fibrinogen
109. Fibrinopeptide B in fibrin assembly and metabolism: physiologic siginficance in delayed release of the peptide
110. Fibrinogen and its derivatives in relationship to ancrod and reptilase
111. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin
112. The Mechanism of Polymerization of Fibrinogen
113. Structure of the fibrin protofibril
114. Evidence for four different polymerization sites involved in human fibrin formation
115. Binding phenomena of isolated unique plasmic degradation products of human cross-lined fibrin
116. Evidence for localization of polymerization sites in fibrinogen
117. Structure of fragment E species from human cross-linked fibrin
118. Fibrinogen Tokyo II. An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules
119. Fibrin polymerization. 1. Alkylating peptide inhibitors of fibrin polymerization
120. Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers
121. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers
122. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites and species differences
123. Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen
124. Localization of a fibrin polymerization site
125. Congenital dysfibrinogenemia: fibrinogen Detroit
126. Effect of calcium and synthetic peptides on fibrin polymerization
127. Identification of an essential histidine residue for fibrin polymerization
128. Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with a deletion Bβ (9–71) corresponding exactly to exon 2 of the gene
129. 2-terminus
130. Complex structure of high affinity polymerization site “a”
131. Localization of a fibrin γ-chain polymerization site within segment Thr-374 to Glu-396 of human fibrinogen
132. Surface markers of fibrinogen and its physiologic derivatives revealed by antibody probes
133. Behaviour of fibrinogen and fibrinogen degradation products (FDP) towards insolubilized fibrinogen and fibrin monomer
134. Fragments D correlation between structure and biological activity
135. Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen
136. Lamprey fibrinogen γ chain: cloning, cDNA sequencing and general characterization
137. On the solubility of fibrin clots
138. Fibrinase. I. Purification of substrate and enzyme
139. Activation of the fibrin-stabilizing factor of plasma by thrombin
140. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation and crosslingking of fibrinogen and fibrin
141. Calcium dependent unmasking of active center cysteine during activation of fibrin stabilizing factor
142. Molecular and catalytic properties of transglutaminases
143. Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures
144. Cross-link fibrin polymerized by factor XIII: ε-(γ-glutamyl)lysine
145. γ-Cross-linking sites in human and bovine fibrin
146. Hybrid fibrin proof of the intermolecular nature of crosslinking units
147. Subunit structure of human fibrinogen, soluble fibrin and cross-linked insoluble fibrin
148. Crosslinking of human fibrin: evidence for intermolecular crosslinking involving α-chains
149. Amino acid sequence studies on the α-chain of human fibrinogen. Isolation and characterization of two linked α-chain cyanogen bromide fragments from fully cross-linked fibrin
150. Localization of the α-chain cross-link acceptor sites of human fibrin
151. Chemical and enzymic detection of protein crosslinks. Measurement of ε-(γ-glutamyl)lysine in fibrin polymerized by factor XIII
152. Fibrin subunits in venous and arterial thromboembolism
153. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique
154. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen
155. Differential binding of plasminogen to crosslinked and non-crosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency
156. Fibronectin and fibrin gel structure
157. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator
158. Effect of fibronectin on adherence of Staphylococcus aureus to fibrin thrombi in vitro
159. 2-plasmin inhibitor to fibrin catalyzed by activated fibrinstablizing factor
160. 2-plasmin inhibitor to fibrin
161. 2-macroglobulin in clottingplasma
162. The purification and mechanism of action of human antithrombin-heparin cofactor
163. Acceleration of the reaction between thrombin and antithrombin III by non-stoichiometric amounts of heparin
164. The role of heparin in the thrombin-antithrombin III reaction
165. Hemorrhagic disorders. I. Protein interactions in the clotting mechanism
166. The interaction of thrombin and heparin. Proflavine dye binding studies
167. Studies on the binding of heparin to prothrombin and thrombin and the effect of heparin-binding on thrombin activity
168. Inhibition of the thrombin-fibrinogen reaction by heparin in the absence of cofactor
169. STUDIES ON BLOOD COAGULATION: II. THE FORMATION OF FIBRIN FROM THROMBIN AND FIBRINOGEN
170. The binding of thrombin by fibrin
171. Studies on the mechanism of thrombin. Interaction with fibrin
172. Immunochemical determination of conformational equilibria for fragments of the Aα chain of fibrinogen
173. 2
174. Selective immobilization of α-thrombin by surface-bound fibrin
175. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
176. Dissociation of esterolytic and clotting activities of thrombin by trypsin-binding macroglobulin
177. 1-proteinase inhibitor
178. Comparison of the inhibition of thrombin by three plasma protease inhibitors
179. High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanisms of their anticoagulant activity
180. Characterization of the inhibition of fibrin assembly by fibrinogen fragment D
181. Characterization of soluble polymerized fibrin formed in the presence of excess fibrinogen fragment D
182. The interference of plasmic degradation products of human crosslinked fibrin with clot formation
183. Inhibition of fibrin polymerization by fragment D is affected by calcium, Gly-Pro-Arg and Gly-His-Arg
184. Inhibition of fibrinogen binding to human platelets by the tetrapeptide glycyl-l-prolyl-l-arginyl-l-proline
185. Fibrinopeptide A binds Gly-Pro-Arg-Pro
186. A study of the inhibitory effect of ethylenediaminetetraacetic acid on the thrombinfibrinogen reaction
187. Effect of EDTA on fibrinogen
188. Human fibrinogen binds EDTA and citrate
189. Influence of pH, ionic strength, neutral ions and thrombin on fibrin polymerization
190. Formation of soluble fibrin oligomers in purified systems and in plasma
191. Calcium and fibrin gel structure
192. Fibrin gel structure and clotting time
193. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen
194. FXIII induced gelatin of human fibrinogen—an alternative thiol enhanced thrombin independent pathway
195. Incorporation of thrombospondin into fibrin clots
196. Platelet interactions with polymerizing fibrin
197. Fibrin network structure: modification by platelets
198. Cofibrins and Fibrin-Intermediates as Indicators of Thrombin Activity in Vivo
199. Soluble unclottable complexes formed in the presence of fibrinogen degradation products (FDP) during the fibrinogen-fibrin conversion and their potential significance in pathology
200. Soluble fibrin complexes: separation as a function of pH and characterization
201. Detection of soluble fibrin in plasma using fibrinogen Sepharose columns
202. Formation and dissociation of soluble fibrin complexes in plasma at 20°C and at 37°C
203. Blood hypercoagulability and thrombosis
204. Formation and detection of fibrinogen derived complexes
205. A rapid chromatographic method for quantitation of high molecular weight fibrinogen derivatives in plasma
206. Origin of soluble crosslinked fibrin oligomers: an in vitro study
207. Separation of human des-AB fibrin and fibrinogen by Sepharose-plasma chromatography at 20 and 37°C
208. Fibrin-fibrinogen interactions during gel filtration in a medium containing fibrinogen, albumin or cold-insoluble globulin
209. The primary structure of human plasminogen: isolation of two lysine-binding fragments and one “mini”-plasminogen (mol wt 38,000) by elastase-catalyzed-specific limited proteolysis
210. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin
211. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degration. Influence of omega amino-carboxylic acids
212. The binding of human plasminogen to fibrin and fibrinogen
213. Cooperative association of plasminogen with fibrinogen
214. Location of plasminogen-binding sites in human fibrinogen
215. The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity
216. 122) segment of fibrinogen is in a region essential for plasminogen binding by fibrin fragment E
217. The fibrin-binding site of human plasminogen. Arginines 32 and 34 are essential for fibrin affinity of the kringle 1 domain
218. Cold-insoluble globulin
219. Interactions among heparin, cold-insoluble globulin and fibrinogen in formation of the heparin-precipitable fraction of plasma
220. Comparison of human plasma fibrinogen subfractions and early plasmic fibrinogen derivatives
221. Binding affinities of human plasma fibronectin, fibrinogen and fibrin monomer
222. Cross-linking of collagen and fibronectin by factor XIII a. Localization of participating glutaminyl residues to a tryptic fragment of fibronectin
223. Chronic intravascular coagulation syndrome
224. Fibroblast adhesion to fibrinogen and fibrin substrata: requirement for cold-insoluble globulin (plasma fibronectin)
225. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen
226. Thrombospondin interactions with fibronectin and fibrinogen. Mutual inhibition of binding
227. Complex formation of platelet thrombospondin with fibrinogen
228. The interaction of human platelet thrombospondin with fibrinogen
229. Effect of fibrinogen on the aggregation of platelets by adenosine diphosphate
230. Influence of fibrinogen on the aggregation of washed human blood platelets induced by adenosine diphosphate, thrombin, collagen, and adrenaline.
231. Immunoelectron microscopic localization of platelet factor 4 and fibrinogen in the granules of human platelets
232. Immunocytochemical localization of fibrinogen platelet factor 4, and β-thromboglobulin in thin frozen sections of human blood platelets
233. Optimal techniques for the immunocytochemical demonstration of β-thromboglobulin, platelet factor 4, and fibrinogen in the α granules of unstimulated platelets
234. Ultrastructural localization of human platelet thrombospondin, fibrinogen, fibronectin and von Willebrand factor in frozen thin section
235. Prostacyclin inhibits mobilization of fibrinogen-binding sites on human ADP and thrombin-treated platelets
236. Participation of ADP in the binding of fibrinogen to thrombinstimulated platelets
237. Fibrinogen and ADP induced platelet aggregation
238. Human platelets possess an inducible and saturable receptor specific for fibrinogen
239. Exposure ofplatelet fibrinogen receptor by ADP and epinephrine
240. A role for prostaglandins and thromboxanes in the exposure of platelet-fibrinogen receptors
241. Platelet aggregation and exposure of fibrinogen receptors by prostagladin endoperoxide analogues
242. Exposure of fibrinogen receptor on human platelets by proteolytic enzymes
243. Fibrinogen interaction with platelet receptors
244. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the γ chain
245. Evidence that three adhesive proteins interact with a common recognization site on activated platelets
246. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets
247. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule
248. The binding of fibrinogen and fibrinogen degradation products to the erythrocyte membrane and its relationship to haemorheology
249. Rheological characteristics of desialylated erythrocytes in relation to fibrinogen-induced aggregation
250. Fibrinogen, a modulator of erythrocyte adhesion to vascular endothelium
251. Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding
252. Fibrin mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell refraction
253. Specific binding of human fibrinogen to cultured human fibroblasts. Evidence for the involvement of the E domain
254. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test
255. Interaction of human fibrinogen with staphylococci: presence of a binding region on normal and abnormal fibrinogen variants and fibrinogen derivatives
256. Identification of a region of human fibrinogen interacting with staphylococcal clumping factor
257. Isolation, characterization and synthesis of peptides from human fibrinogen that block the staphylococcal clumping reaction and construction of a synthetic clumping particle
258. Fibrinogen and its fragment D stimulate proliferation of human hemopoietic cells in vitro
259. Association of fibrin with the platelet cytoskeleton
260. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen
261. On the regulation and control of fibrinolysis
262. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin
263. Fibrinogen properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator
264. Kinetics of the activation of plasminogen by natural and recombinant tissue-tyep plasminogen activator
265. Initial plasmin-degradation of fibrin as the basis of a postive feedback mechanism in fibrinolysis
266. Activation of plasminogen by tissue activator is increased specifically in the presence of certain soluble fibrin(ogen) fragments
267. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activition by tissue-type plasminogen activator
268. Importance of intramolecular interactions in the control of the fibrin affinity and activation of human plasminogen
269. Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/celite
270. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine
271. 2+ for a binding interaction between urokinase-type plasminogen activator and fibrin
272. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase)
273. Biological and thrombolytic properties of proenzyme and active forms of human urokinase I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology
274. Le produits de degradation du fibrinogene humain par la plasmine. I. Separation et proprietes physico-chimiques
275. High molecular weight products of the late stage of fibrinogen proteolysis by plasmin and their structural relation to the fibrinogen molecule
276. The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage
277. Immunologic structure of fibrinogen and its plasmin degradation products. Theoretical and clinical considerations
278. Heterogeneity of human fibrinogen: possible relation to proteolysis by thrombin and plasmin as studied by SDS-polyacrylamide gel electrophoresis
279. A structural aspect of human fibrinogen suggested by its plasmin degradation
280. Ultracentrifuge studies on the reaction between thrombin and plasminized fibrinogen
281. Fate of fibrinopeptides in the reaction between human plasmin and fibrinogen
282. Identification and purification of fibrinogen degradation products produced by plasmin. Considerations on the structure of fibrinogen
283. Relative proteolysis of the fibrinogen B chain by thrombin and plasmin as a determinant of thrombosis
284. 2-terminus of the Bβ chain of human fibrinogen
285. The release of Bβ 1–42 from fibrinogen and fibrin by plasmin
286. Subunit structure of fragment D from fibrinogen and cross-linked fibrin
287. Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino terminal sequences of intermediate and terminal fragments
288. Plasmic degradation of human fibrinogen. II. Further characterization of fragment D
289. Primary structure of human fibrinogen and fibrin. Isolation and partial characterization of chains of fragment D
290. Affinity chromatography of fibrinogen plasminolysis fragment D
291. Comparison of the physicochemical properties of fragment D derivatives of fibrinogen and fragment D-D of cross-linked fibrin
292. Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis
293. Primary soluble plasmic degradation product of human crosslinked fibrin. Isolation and stoichiometry of the (DD) E complex
294. Characterization and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin
295. The effect of plasmin on the subunit structure of human fibrin
296. Degradation of fibrinogen by plasmin. Isolation of an early cleavage product
297. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure
298. Plasmic degradation of crosslinked fibrin. I. Structure analysis of the particulate clot and identification of new macromolecular soluble complexes
299. 1 by venous thrombi in pigs
300. 123I in the detection of venous thrombosis
301. Action of water-insoluble trypsin derivatives on fibrinogen clottability
302. The structure of the fibrinogen degradation products
303. Proteolytic fragmentation of fibrinogen. I. Comparison of the fragmentation of human and bovine fibrinogen by trypsin or plasmin
304. Digestion of fibrinogen by trypsin. II. Characterization of the large fragment obtained
305. Kinetic studies of the digestion of fibrinogen by α-chymotrypsin
306. Human factor XIa cleaves fibrinogen: effects on structure and function.
307. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH
308. Unique pattern of fibrinogen cleavage by human leukocyte proteases
309. Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes
310. Anticoagulant properties of purified X-like fragments of human fibrinogen produced by degradation with leukocyte elastase
311. Cleavage of fibrinogen by the human neutrophil neutral peptide-generating protease.
312. Purification and partial characterization of a D-like fragment from human fibrinogen, produced by human leukocyte elastase
313. Cleavage of fibrinogen by human platelet calcium-activated protease
314. Composition of salivary gland extracts from the leech Haementeria ghilianii
315. Hementin: anticoagulant protease from the salivary gland of the leech Haementeria ghilianii
316. Anticoagulant and fibrinolytic properties of salivary proteins from the leech Haementeria ghilianii
317. Fibrinogen degradation by hementin, a fibrinogenolytic anticoagulant from the salivary gland of the leech Haementeria ghilianii
318. Anticoagulant proteases from western diamondback rattlesnake (Crotalus atrox) venom
319. A study of fibrinogen production by human liver slices in vitro by an immunoprecipitin method
320. 125I-labeled fibrinogen
321. Normal reference laboratory values
322. The phenomenon of the acute phase response
323. Interleukin-1 and the pathogenesis of the acute-phase response
324. The measurement of absolute and relative synthesis rates of fibrinogen in vivo
325. Structural analysis of fibrinogen synthesized by cultured chicken hepatocytes in the presence or absence of dexamethasone
326. Xenopus fibrinogen. Characterization of subunits and hormonal regulation of biosynthesis
327. Stimulation of fibrinogen synthesis: a possible role of fibrinogen degradation products
328. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway
329. Stimulation of fibrinogen biosynthesis by fibrinogen fragments D and E
330. HEPATOCYTE-STIMULATING FACTOR: A MONOCYTE-DERIVED ACUTE-PHASE REGULATORY PROTEIN
331. Platelet and plasma fibrinogens are identical gene products
332. Common structural genes for platelet and plasma fibrinogen
333. Plasma and platelet fibrinogen differ in γ-chain content
334. Human platelet fibrinogen γ-chain structure
335. Fibrinogen biosynthesis in isolated guinea pig megakaryocytes
336. Fibrinogen synthesis by megakaryocyte rich human marrow cell concentrate
337. Effects of variant γ chains and sialic acid content of fibrinogen upon its interactions with ADP-stimulated human and rabbit platelets
338. Studies of platelet fibrinogen from a subject with a congental plasma fibrinogen abnormality (fibrinogen Paris I)
339. In vitro synthesis of rat fibrinogen: identification of preAα, preBβ, and prey polypeptides
340. Rabbit fibrinogen: time course of constituent chain production in vivo
341. Intracellular assembly of human fibrinogen
342. Fibrinogen precursors. Order of assembly of fibrinogen chains
343. Biosynthesis of dog fibrinogen. Characterization of nascent fibrinogen in the rough endoplasmic reticulum
344. Modification of fibrinogen chains during synthesis: glycosylation of Bβ and γ chains
345. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans
346. Kinetic characterization of a saturable pathyway for rapid clearance of circulating fibrin monomer
347. The biological significance of fibrinolysis
348. Adsorptive endocytosis of fibrin monomer by macrophages: evidence of a receptor for the amino terminus of the fibrin α chain
349. Fibronectin (cold-insoluble globulin), mediation of fibrin-monomer binding to macrophages
350. 2-surface binding glycoprotein deficiency in septic surgical and trauma patients
351. The preparation and properties of human fibrinogen of relatively high solubility
352. Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates
353. Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components
354. Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease
355. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma
356. Human fibrinogen heterogeneities: determination of the major Aα chain derivatives in blood
357. Quantitation of the three normally occurring plasma fibrinogens in health and during so-called “acute phase” by SDS
358. Haemostatic function and cardiovascular death: early results of a prospective study
359. Fibrinogen as a risk factor for stroke and myocardial infarction
360. Time course of reversibility of accelerated fibrinogen disappearance in diabetes mellitus: association with intravascular volume shifts
361. Tissue plasminogen activator (t-PA). Will it fulfill its promise?
362. Continuous cultures of fused cells secreting antibody of predefined specificity
363. Preparation of monoclonal antibodies: strategies and procedures
364. 2-terminal region of fibrin
365. Radioimmunoimaging of venous thrombi using iodine-131 monoclonal antibody
366. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen
367. Antibody-directed urokinase: a specific fibrinolytic agent
368. 2-terminal fragments derived from fibrinogen and fibrin
369. A monoclonal antibody, specific for human fibrinogen, fibrinopeptide A-containing fragments and not reacting with free fibrinopeptide A
370. Monoclonal antibody to the region of fibronectin involved in cross-linking to human fibrin
371. Monoclonal antibodies to α-chain regions of human fibrinogen that participate in polymer formation
372. Measurement of cross-linked fibrin degradation products—an immunoassay using monoclonal antibodies